3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:百万円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 10,065 | 9,420 |
受取手形及び売掛金 | 6,242 | 6,209 |
商品及び製品 | 834 | 785 |
仕掛品 | 77 | 64 |
原材料及び貯蔵品 | 555 | 464 |
その他 | 1,452 | 1,286 |
貸倒引当金 | △0 | △0 |
流動資産合計 | 19,226 | 18,228 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 9,372 | 9,397 |
減価償却累計額 | △4,887 | △5,157 |
建物及び構築物(純額) | 4,484 | 4,239 |
工具、器具及び備品 | 4,298 | 4,616 |
減価償却累計額 | △3,699 | △3,727 |
工具、器具及び備品(純額) | 598 | 889 |
土地 | 5,370 | 5,382 |
リース資産 | 1,355 | 1,327 |
減価償却累計額 | △1,097 | △1,208 |
リース資産(純額) | 258 | 119 |
建設仮勘定 | 300 | 471 |
その他 | 28 | 201 |
減価償却累計額 | △16 | △36 |
その他(純額) | 11 | 164 |
有形固定資産合計 | 11,023 | 11,267 |
無形固定資産 | | |
のれん | 23 | - |
ソフトウエア | 302 | 419 |
その他 | 11 | 123 |
無形固定資産合計 | 337 | 543 |
投資その他の資産 | | |
投資有価証券 | 3,616 | 3,675 |
繰延税金資産 | 902 | 982 |
その他 | 1,322 | 1,325 |
貸倒引当金 | △4 | △4 |
投資その他の資産合計 | 5,837 | 5,979 |
固定資産合計 | 17,199 | 17,790 |
資産合計 | 36,425 | 36,019 |
| | (単位:百万円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
負債の部 | | |
流動負債 | | |
支払手形及び買掛金 | 4,414 | 4,284 |
短期借入金 | 500 | 400 |
リース債務 | 169 | 59 |
未払金 | 793 | 733 |
未払法人税等 | 378 | 525 |
賞与引当金 | 496 | 482 |
その他 | 1,012 | 947 |
流動負債合計 | 7,764 | 7,432 |
固定負債 | | |
長期借入金 | - | 844 |
リース債務 | 148 | 134 |
繰延税金負債 | 319 | 292 |
退職給付に係る負債 | 1,760 | 1,652 |
資産除去債務 | 83 | 84 |
その他 | 322 | 323 |
固定負債合計 | 2,634 | 3,332 |
負債合計 | 10,398 | 10,765 |
純資産の部 | | |
株主資本 | | |
資本金 | 3,371 | 3,371 |
資本剰余金 | 3,307 | 3,307 |
利益剰余金 | 19,447 | 19,485 |
自己株式 | △821 | △1,586 |
株主資本合計 | 25,305 | 24,577 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 642 | 603 |
その他の包括利益累計額合計 | 642 | 603 |
新株予約権 | 78 | 72 |
純資産合計 | 26,026 | 25,253 |
負債純資産合計 | 36,425 | 36,019 |
E0498246710株式会社ファルコホールディングスFALCO HOLDINGS Co., Ltd.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse467102024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember467102024-03-31jpcrp_cor:ReportableSegmentsMember467102023-04-012024-03-31jpcrp_cor:ReportableSegmentsMember467102025-03-31jpcrp_cor:ReportableSegmentsMember467102024-04-012025-03-31tse-acedjpfr-46710:ClinicalTestingBusinessReportableSegmentsMember467102024-04-012025-03-31tse-acedjpfr-46710:DispensingPharmacyBusinessReportableSegmentsMember467102024-04-012025-03-31tse-acedjpfr-46710:ICTBusinessReportableSegmentsMember467102024-03-31tse-acedjpfr-46710:ClinicalTestingBusinessReportableSegmentsMember467102024-03-31tse-acedjpfr-46710:DispensingPharmacyBusinessReportableSegmentsMember467102024-03-31tse-acedjpfr-46710:ICTBusinessReportableSegmentsMember467102023-04-012024-03-31tse-acedjpfr-46710:ClinicalTestingBusinessReportableSegmentsMember467102023-04-012024-03-31tse-acedjpfr-46710:DispensingPharmacyBusinessReportableSegmentsMember467102023-04-012024-03-31tse-acedjpfr-46710:ICTBusinessReportableSegmentsMember467102025-03-31tse-acedjpfr-46710:ClinicalTestingBusinessReportableSegmentsMember467102025-03-31tse-acedjpfr-46710:DispensingPharmacyBusinessReportableSegmentsMember467102025-03-31tse-acedjpfr-46710:ICTBusinessReportableSegmentsMember467102024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember467102024-03-31jpcrp_cor:ReconcilingItemsMember467102023-04-012024-03-31jpcrp_cor:ReconcilingItemsMember467102025-03-31jpcrp_cor:ReconcilingItemsMember467102024-04-012025-03-31jppfs_cor:CapitalStockMember467102024-04-012025-03-31jppfs_cor:CapitalSurplusMember467102024-04-012025-03-31jppfs_cor:RetainedEarningsMember467102024-04-012025-03-31jppfs_cor:TreasuryStockMember467102025-03-31jppfs_cor:SubscriptionRightsToSharesMember467102024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember467102024-03-31jppfs_cor:SubscriptionRightsToSharesMember467102024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember467102024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember467102024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember467102023-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember467102023-03-31jppfs_cor:CapitalStockMember467102023-03-31jppfs_cor:CapitalSurplusMember467102023-03-31jppfs_cor:RetainedEarningsMember467102023-03-31jppfs_cor:TreasuryStockMember467102023-03-31jppfs_cor:ShareholdersEquityMember467102023-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember467102023-04-012024-03-31jppfs_cor:CapitalStockMember467102023-04-012024-03-31jppfs_cor:CapitalSurplusMember467102023-04-012024-03-31jppfs_cor:TreasuryStockMember467102023-04-012024-03-31jppfs_cor:RetainedEarningsMember467102024-04-012025-03-31jppfs_cor:ShareholdersEquityMember467102023-04-012024-03-31jppfs_cor:ShareholdersEquityMember467102024-03-31jppfs_cor:CapitalStockMember467102023-04-012024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember467102023-04-012024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember467102025-03-31jppfs_cor:ShareholdersEquityMember467102025-03-31jppfs_cor:CapitalStockMember467102025-03-31jppfs_cor:CapitalSurplusMember467102025-03-31jppfs_cor:RetainedEarningsMember467102025-03-31jppfs_cor:TreasuryStockMember467102023-04-012024-03-31jppfs_cor:SubscriptionRightsToSharesMember467102023-03-31jppfs_cor:SubscriptionRightsToSharesMember467102025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember467102025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember467102024-03-31jppfs_cor:CapitalSurplusMember467102024-03-31jppfs_cor:RetainedEarningsMember467102024-03-31jppfs_cor:TreasuryStockMember467102024-03-31jppfs_cor:ShareholdersEquityMember467102024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember467102024-04-012025-03-31467102024-03-31467102023-04-012024-03-31467102023-03-31467102025-05-13467102025-03-31xbrli:pureiso4217:JPY